Clinical Trials
34 trialsNCT07618546 2026-06-01
A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors
Henan Cancer Hospital
Phase NA Not yet recruiting
NCT07610629 2026-05-28
RA-A-NP
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT05223088 2025-03-18
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IVăLarge Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Completed
NCT06786312 2025-01-22
A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT03228043 2024-11-14
Apatinib for Resectable Colorectal Cancer
Nanchong Central Hospital
Phase NA Withdrawn
NCT05019690 2024-09-19
Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer
Fujian Cancer Hospital
Phase 1/2 Recruiting
NCT06538935 2024-08-06
SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06539091 2024-08-06
Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer
Anhui Provincial Hospital
Phase 3 Not yet recruiting
NCT05699655 2024-05-01
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IVăLarge Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2/3 Recruiting
NCT05597527 2022-10-28
Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT05380986 2022-05-19
Camrelizumab Combined With Apatinib Mesylate
Henan Cancer Hospital
Phase NA Unknown
NCT04901754 2021-12-08
CAMERA
Henan Cancer Hospital
Phase 2 Unknown
NCT04832204 2021-04-05
Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases
Beijing Hospital
Phase 2 Unknown
NCT03389087 2020-07-10
Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT03397199 2020-04-15
Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT04174339 2019-11-22
PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer
Fujian Cancer Hospital
Phase NA Unknown
NCT04121039 2019-10-09
Study of the Apatinib Combine With POF Versus POF in Gastric Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT04089657 2019-09-13
ASGARD
Fujian Cancer Hospital
Phase 2 Unknown
NCT03986515 2019-06-14
Apatinib Plus SHR1210 in Advanced Mucosal Melanoma
Henan Cancer Hospital
Phase 2 Unknown
NCT03954756 2019-05-17
Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT03950141 2019-05-15
Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer
Beijing Hospital
Phase 2 Unknown
NCT03942068 2019-05-08
Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT02697838 2018-10-17
Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT03599778 2018-07-26
XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma
Anhui Provincial Hospital
Phase 1/2 Unknown
NCT03546855 2018-06-06
Apatinib Treating Patients With Advanced Cervical Cancer After Radiotherapy and First-line Chemotherapy.
Anhui Provincial Hospital
Phase 2 Unknown
NCT03547375 2018-06-06
Clinical Study of Apatinib in the Treatment of Advanced Ovarian Cancer After the Failure of Standard Chemotherapy
Anhui Provincial Hospital
Phase 2 Unknown
NCT03424291 2018-02-06
A Retrospective Clinical Study of Apatinib in Combination With Radiotherapy / Chemotherapy Second-line and Above in the Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
Henan Cancer Hospital
Phase 2 Unknown
NCT03383237 2017-12-27
Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma
Henan Cancer Hospital
Phase 2 Unknown
NCT03376737 2017-12-18
Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma
Henan Cancer Hospital
Phase 2 Unknown
NCT03334591 2017-11-14
Research On the Optimized Treatment Method For Apatinib's Cure Of Advanced Gastric Cancer
Anhui Provincial Hospital
Phase 2 Unknown
NCT03170310 2017-05-31
Apatinib Treatment for Advanced Esophagus Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT03163381 2017-05-23
Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.
Henan Cancer Hospital
Phase 2 Unknown
NCT03030937 2017-01-25
Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA
Fujian Cancer Hospital
Phase 2 Unknown
NCT02980809 2016-12-02
Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer
First Hospitals affiliated to the China PLA General Hospital
Phase 2 Unknown